COVID-19医薬品関連APIの世界市場レポート 2024

COVID-19医薬品関連APIの市場規模は、今後数年間で大幅に成長すると予想されます。 2028年には6.0%の年間複合成長率（CAGR）で85億2,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、いくつかの重要な要因によってもたらされると予想されます。これには、COVID-19治療薬の新しい治療法の開発、COVID-19治療の可能性を探る臨床試験の急増、COVID-19ワクチンの継続的な需要の増加、継続的な研究や医薬品開発を必要とする新型ウイルスの出現、広範な予防接種を目指すワクチン接種キャンペーン、パンデミック対策への注目の高まりなどが含まれます。

抗レトロウイルス薬、抗マラリア薬、呼吸器薬などの主要医薬品の需要が急増しているため、COVID-19治療薬の製造に不可欠な医薬品有効成分（API）の必要性が高まっています。レムデシビルとファビピラビルは、COVID-19の治療に使用される著名な抗ウイルス薬の一つです。レムデシビルは米国と日本で緊急承認を取得し、FDAはエアスープラを気管支収縮と喘息予防として承認しました。新型コロナウイルス感染症（COVID-19）による呼吸器への影響により、気管支拡張薬の需要が大幅に増加しました。その結果、抗ウイルス薬、抗マラリア薬、気管支拡張薬に対する需要の増加により、COVID-19医薬品関連APIの市場が牽引されると予想されます。

ヘルスケアの研究開発に焦点を当てた政府の取り組みが、COVID-19医薬品関連API市場の成長を促進することになるでしょう。これらの取り組みには、ヘルスケアニーズに対処するために政府機関が実施する特定のプログラム、政策、または行動が含まれます。たとえば、英国政府は2022年に、ヘルスケア主導の健康調査、診断、ライフサイエンス製造の支援を目的として、医療調査と製造の強化に2億6,000万ポンドを割り当てました。このような取り組みは、COVID-19医薬品関連APIの開発、生産、流通に役立つ環境を促進する上で極めて重要です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のCOVID-19医薬品関連API市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 抗マラリア薬
• 気管支拡張薬
• 抗生物質
• 抗ウイルス薬
• その他の薬剤クラス
• 世界のCOVID-19医薬品関連API市場、合成タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 合成
• バイオテクノロジー
• 世界のCOVID-19医薬品関連API市場、ビジネスモード別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• キャプティブAPI
• マーチャントAPI

第7章 地域および国の分析

• 世界のCOVID-19医薬品関連API市場、地域別、実績および予測、2018年から2023年、2023年から2028年、2033年
• 世界のCOVID-19医薬品関連API市場、国別、実績および予測、2018年から2023年、2023年から2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• COVID-19医薬品関連API市場の競合情勢
• COVID-19医薬品関連API市場の企業プロファイル
  • Dr. Reddy's Laboratories Ltd.
  • Lianyungang Guile Pharmaceutical CO. LTD.
  • Alembic Pharmaceuticals Ltd.
  • Wockhardt Ltd.
  • Sandoz Srl

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

COVID-19 drug-associated APIs constitute the active pharmaceutical ingredients utilized in the formulation of medications targeting the virus. These APIs serve as the fundamental chemical components responsible for the pharmacological effects within the human body.

The primary classes of drugs categorized as COVID-19 drug-associated APIs encompass antimalarials, bronchodilators, antibiotics, antivirals, and other related categories. Antimalarial drugs, specifically, are antiparasitic agents used to treat or prevent malaria, commonly sourced from organic origins. These drugs exist in various forms, including generic and branded versions, and are involved in different business models such as captive API (produced for internal use) and merchant API (commercially available for external sales).

The COVID-19 drug-associated APIs market research report is one of a series of new reports from The Business Research Company that provides COVID-19 drug-associated APIs market statistics, including global market size, regional shares, competitors with a COVID-19 drug-associated APIs market share, detailed COVID-19 drug-associated APIs market segments, COVID-19 drug-associated APIs market trends and opportunities, and any further data you may need to thrive in the COVID-19 drug-associated APIs industry. This COVID-19 drug-associated APIs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The COVID-19 drug associated apis market size has grown strongly in recent years. It will grow from $6.37 billion in 2023 to $6.75 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. The growth observed in the historical period can be primarily attributed to several key factors. These include the increasing prevalence of COVID-19 infections, heightened awareness regarding treatment options available for COVID-19, expanded accessibility to drugs targeting the virus, a growing demand for COVID-19 medications used as prophylaxis, government initiatives supporting healthcare measures, and efforts to strengthen the resilience of the supply chain for these drugs. These factors collectively contributed to the growth and development of the market for COVID-19 drug-associated APIs during that period.

The COVID-19 drug associated apis market size is expected to see strongly grown in the next few years. It will grow to $8.52 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The anticipated growth in the forecast period is expected to stem from several significant factors. These include the development of novel modalities for COVID-19 drugs, a surge in clinical trials exploring potential COVID-19 treatments, a continued rise in demand for COVID-19 vaccines, the emergence of new virus variants necessitating ongoing research and drug development, vaccination campaigns aiming for widespread immunization, and a heightened focus on pandemic preparedness measures.

The surging demand for key pharmaceuticals like antiretrovirals, antimalarials, and respiratory drugs has led to increased need for active pharmaceutical ingredients (APIs) crucial in manufacturing COVID-19 medications. Remdesivir and Favipiravir are among the prominent antiviral drugs used for COVID-19 treatment. Remdesivir gained emergency approval in the USA and Japan, while the FDA approved Airsupra for bronchoconstriction and asthma prevention. The demand for bronchodilators escalated significantly due to COVID-19's respiratory impact. Consequently, this increased demand for antivirals, antimalarials, and bronchodilators is expected to drive the market for COVID-19 drug-associated APIs.

Government initiatives focused on healthcare research and development are set to fuel growth in the COVID-19 drug-associated API market. These initiatives encompass specific programs, policies, or actions undertaken by government bodies to address healthcare needs. For instance, in 2022, the UK government allocated £260 million to bolster healthcare research and manufacture, aiming to support NHS-led health research, diagnostics, and life sciences manufacturing. Such initiatives are pivotal in fostering an environment conducive to the development, production, and distribution of COVID-19 drug-associated APIs.

Major pharmaceutical players are strategizing capacity expansions to meet the escalating demand for COVID-19 drug-related APIs amid rising global COVID-19 cases. Merck & Co., Inc., in partnership with India's Heavy Water Board, aims to delve into the deuterated raw compound industry, potentially worth $1 billion in the next decade. Merck aims to support sectors like chemicals, pharmaceuticals, and electronics by supplying high-quality compounds. Avigan, currently undergoing clinical trials, is being tested for its effectiveness in treating COVID-19 patients.

Top companies in the COVID-19 drug-associated APIs market are focusing on innovation, such as oral treatments, to gain a competitive advantage. In 2023, Pfizer Inc.'s PAXLOVID, an oral SARS-CoV-2 protease inhibitor approved by the FDA, demonstrated an 89% reduction in hospitalization or death risk compared to a placebo in high-risk, non-hospitalized adults with COVID-19. Designed for early administration, it aims to prevent severe illness and hospitalization, making a significant impact in managing the infection.

In January 2023, Sterling Pharma Solutions, a US-based pharmaceutical company, completed the acquisition of an undisclosed active pharmaceutical ingredient (API) manufacturing facility from Novartis, a prominent pharmaceutical company based in the US. This strategic acquisition marks an expansion of Sterling's capabilities in API manufacturing. The deal also includes a continued supply arrangement between Sterling and Novartis, ensuring the manufacturing of several APIs utilized in cardiovascular, immunology, and oncology medications. Novartis AG, known for its production of active pharmaceutical ingredients, initiated this transfer as part of their strategic reorganization.

Major companies operating in the COVID-19 drug associated apis market include Dr. Reddy's Laboratories Ltd., Lianyungang Guike Pharmaceutical CO. LTD., Alembic Pharmaceuticals Ltd., Wockhardt Ltd., Sandoz Srl, Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical Co. Ltd., Zhejiang Yatai Pharmaceutical Co. Ltd., Zhejiang Guobang Pharmaceutical Co Ltd., Cipla Limited, Shandong Boyuan Pharmaceutical Co. Ltd., Aspiro Pharma Ltd., Qilu Antibiotics Pharmaceutical Co. Ltd., Shenzhen China Resources Jiuxin Pharmaceutical Co. Ltd., Zhejiang Cheng Yi Pharmaceutical, Star Lake Bioscience Co.Inc., Hetero Labs Ltd., Geno Pharmaceuticals Ltd., Mylan Laboratories Ltd., Ipca Laboratories Limited, Zydus Takeda Healthcare Private Limited, Mangalam Drugs & Organics, Wallace Pharmaceuticals, Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Jiuzhou Pharmaceutical Co. Ltd., Zhejiang NHU Co. Ltd., Zhejiang Xianju Pharmaceutical Co. Ltd., Zhejiang Yongtai Technology Co. Ltd., Zhejiang Zhebei Pharmaceutical Co. Ltd., Zhejiang Tianyu Pharmaceutical Co. Ltd., Zhejiang Aisheng Pharmaceutical Co. Ltd., Zhejiang Aokang Pharmaceutical Co. Ltd., Zhejiang Anji Huifeng Surgical Dressings Co. Ltd.

North America was the largest region in the COVID-19 drug-associated APIs market in 2023. Middle East is expected to be the fastest growing region in the global COVID-19 drug associated apis market share during the forecast period. The regions covered in the COVID-19 drug associated apis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the COVID-19 drug associated apis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The COVID-19 drug-associated APIs market consists of sales of acetaminophen (Tylenol) and ibuprofen (Motrin, Advil). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

COVID-19 Drug Associated APIs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on covid-19 drug associated apis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for covid-19 drug associated apis? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The covid-19 drug associated apis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Drug Class: Antimalarials; Bronchodilators; Antibiotics; Antivirals; Other Drug Class
• 2) By Synthesis Type: Synthetic; Biotech
• 3) By Business Mode: Captive API; Merchant API
• Companies Mentioned: Dr. Reddy's Laboratories Ltd.; Lianyungang Guike Pharmaceutical CO. LTD.; Alembic Pharmaceuticals Ltd.; Wockhardt Ltd.; Sandoz Srl
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. COVID-19 Drug Associated APIs Market Characteristics

3. COVID-19 Drug Associated APIs Market Trends And Strategies

4. COVID-19 Drug Associated APIs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global COVID-19 Drug Associated APIs Market Size and Growth

• 5.1. Global COVID-19 Drug Associated APIs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global COVID-19 Drug Associated APIs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global COVID-19 Drug Associated APIs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. COVID-19 Drug Associated APIs Market Segmentation

• 6.1. Global COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Antimalarials
• Bronchodilators
• Antibiotics
• Antivirals
• Other Drug Class
• 6.2. Global COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Synthetic
• Biotech
• 6.3. Global COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Captive API
• Merchant API

7. COVID-19 Drug Associated APIs Market Regional And Country Analysis

• 7.1. Global COVID-19 Drug Associated APIs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global COVID-19 Drug Associated APIs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific COVID-19 Drug Associated APIs Market

• 8.1. Asia-Pacific COVID-19 Drug Associated APIs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China COVID-19 Drug Associated APIs Market

• 9.1. China COVID-19 Drug Associated APIs Market Overview
• 9.2. China COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India COVID-19 Drug Associated APIs Market

• 10.1. India COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan COVID-19 Drug Associated APIs Market

• 11.1. Japan COVID-19 Drug Associated APIs Market Overview
• 11.2. Japan COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia COVID-19 Drug Associated APIs Market

• 12.1. Australia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia COVID-19 Drug Associated APIs Market

• 13.1. Indonesia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea COVID-19 Drug Associated APIs Market

• 14.1. South Korea COVID-19 Drug Associated APIs Market Overview
• 14.2. South Korea COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe COVID-19 Drug Associated APIs Market

• 15.1. Western Europe COVID-19 Drug Associated APIs Market Overview
• 15.2. Western Europe COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK COVID-19 Drug Associated APIs Market

• 16.1. UK COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany COVID-19 Drug Associated APIs Market

• 17.1. Germany COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France COVID-19 Drug Associated APIs Market

• 18.1. France COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy COVID-19 Drug Associated APIs Market

• 19.1. Italy COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain COVID-19 Drug Associated APIs Market

• 20.1. Spain COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe COVID-19 Drug Associated APIs Market

• 21.1. Eastern Europe COVID-19 Drug Associated APIs Market Overview
• 21.2. Eastern Europe COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia COVID-19 Drug Associated APIs Market

• 22.1. Russia COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America COVID-19 Drug Associated APIs Market

• 23.1. North America COVID-19 Drug Associated APIs Market Overview
• 23.2. North America COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA COVID-19 Drug Associated APIs Market

• 24.1. USA COVID-19 Drug Associated APIs Market Overview
• 24.2. USA COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada COVID-19 Drug Associated APIs Market

• 25.1. Canada COVID-19 Drug Associated APIs Market Overview
• 25.2. Canada COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America COVID-19 Drug Associated APIs Market

• 26.1. South America COVID-19 Drug Associated APIs Market Overview
• 26.2. South America COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil COVID-19 Drug Associated APIs Market

• 27.1. Brazil COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East COVID-19 Drug Associated APIs Market

• 28.1. Middle East COVID-19 Drug Associated APIs Market Overview
• 28.2. Middle East COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa COVID-19 Drug Associated APIs Market

• 29.1. Africa COVID-19 Drug Associated APIs Market Overview
• 29.2. Africa COVID-19 Drug Associated APIs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa COVID-19 Drug Associated APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa COVID-19 Drug Associated APIs Market, Segmentation By Business Mode, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. COVID-19 Drug Associated APIs Market Competitive Landscape And Company Profiles

• 30.1. COVID-19 Drug Associated APIs Market Competitive Landscape
• 30.2. COVID-19 Drug Associated APIs Market Company Profiles
  • 30.2.1. Dr. Reddy's Laboratories Ltd.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Lianyungang Guile Pharmaceutical CO. LTD.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Alembic Pharmaceuticals Ltd.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Wockhardt Ltd.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Sandoz Srl
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global COVID-19 Drug Associated APIs Market Competitive Benchmarking

32. Global COVID-19 Drug Associated APIs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The COVID-19 Drug Associated APIs Market

34. COVID-19 Drug Associated APIs Market Future Outlook and Potential Analysis

• 34.1 COVID-19 Drug Associated APIs Market In 2028 - Countries Offering Most New Opportunities
• 34.2 COVID-19 Drug Associated APIs Market In 2028 - Segments Offering Most New Opportunities
• 34.3 COVID-19 Drug Associated APIs Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer